Compare
The details that actually shape the buying decision.
Evidence, risk, regulatory flags, cost, and vendor coverage — side by side, without affiliate spin.
01· Subject
Thymosin Beta-4
Actin-sequestering peptide with clinical data in ophthalmic wound healing and preclinical tissue repair.
Tier B-Cmed-high risk
02· Subject
BPC-157
Preclinical cytoprotective peptide studied for tissue repair and GI protection in animal models.
Tier Cmed-high risk
01 · At a glance
| Decision factor | Thymosin Beta-4 | BPC-157 | TB-500 |
|---|---|---|---|
| Primary fit | tissue repair & recovery and immune support comparisons | tissue repair & recovery research where you want a clear starting point | tissue repair & recovery research where you want a clear starting point |
| Evidence | Tier B-C | Tier C | Tier C |
| Risk | med-high | med-high | med-high |
| Experience level | intermediate | intermediate | intermediate |
| Budget tier | mid | mid | mid |
| Administration route | topical, subcutaneous | subcutaneous, oral | subcutaneous |
02 · Use case & timing
| Decision factor | Thymosin Beta-4 | BPC-157 | TB-500 |
|---|---|---|---|
| Goal fit | Tissue Repair & Recovery, Immune Support | Tissue Repair & Recovery | Tissue Repair & Recovery |
| What users compare it for | Ophthalmic: improved corneal epithelial healing. Systemic: wound healing signals in preclinical models. | Preclinical: angiogenesis markers, tissue repair signals, GI mucosal protection in rodent models. | Soft-tissue repair and recovery signals in preclinical models. |
| Onset timeline | Corneal healing studies: days to weeks; systemic repair claims are less well-timed. | Animal models: endpoints assessed over days to weeks (2-4 weeks in injury models). | Preclinical: varies by injury model. Consumer timelines are speculative. |
| Main tradeoff | Evidence and product availability can still be uneven, so documentation matters more than hype. | Evidence and product availability can still be uneven, so documentation matters more than hype. | Evidence and product availability can still be uneven, so documentation matters more than hype. |
03 · Safety & restrictions
| Decision factor | Thymosin Beta-4 | BPC-157 | TB-500 |
|---|---|---|---|
| Adverse effects | Human ophthalmic safety reported as acceptable in trials; systemic safety requires caution. | Insufficient human data; immunogenicity risk flagged by FDA; impurity characterization concerns. | Limited safety data; sequence ambiguity adds quality risk. |
| Contraindications | Limited formal contraindication data. | No established human contraindications (insufficient data). | No established contraindications (insufficient data). |
| Interaction notes | Limited formal interaction studies; treat as unknown outside studied settings. | No robust human interaction map; avoid confident stacking claims. | Unknown/insufficient. Caution when combining with full-length thymosin beta-4 due to sequence overlap. |
| Regulatory status | Investigational | Not approved | Not approved |
| FDA flag | FDA compounding caution | FDA compounding caution | FDA status unclear |
| WADA status | WADA S2 | WADA S0 | WADA S2 |
04 · Age & monitoring
| Decision factor | Thymosin Beta-4 | BPC-157 | TB-500 |
|---|---|---|---|
| Supported age ranges | No age guidance yet | 25-34, 35-44, 45-54, 55-64 | 25-34, 35-44, 45-54, 55-64 |
| Life-stage note | Not yet documented | Commonly researched by active adults for recovery, but still lacks validated human age-specific evidence. | Usually framed as a recovery compound for active adults rather than a later-life maintenance tool. |
| Monitoring burden | Not specified | Not specified | Not specified |
| Follow-up cadence | Not yet documented | Not yet documented | Not yet documented |
05 · Cost & sourcing
| Decision factor | Thymosin Beta-4 | BPC-157 | TB-500 |
|---|---|---|---|
| Typical cycle cost | $192.00 | $118.99 | $287.97 |
| Estimated monthly cost | $96.00 | $79.32 | $143.98 |
| Cost confidence | High confidence | High confidence | High confidence |
06 · Before you buy
| Decision factor | Thymosin Beta-4 | BPC-157 | TB-500 |
|---|---|---|---|
| Tracked vendor listings | 1 listing | 3 listings | 3 listings |
| Sourcing note | Product format varies by listing, so double-check route, concentration, and presentation. | Product format varies by listing, so double-check route, concentration, and presentation. | Product format varies by listing, so double-check route, concentration, and presentation. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly | Usually stack-friendly |
Still deciding
Get a plan tailored to you.
Side-by-side narrows the field. The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.